BIOSPAIN 2026

ICO: fondo españa Crece, préstamos subordinados adecuados al tipo de proyecto
BEI: Innothink
BME,
Santiago de Torres ATRYS
OCA

Meet early stage companiesseeking seed/series A funding

Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.

---

• Backpacked-Antibody platform  – Izaskun Morillo, Postdoctoral Researcher
• Exitium Therapeutics  – Angélica Figueroa Conde-Valvís, CSO
• Korum Diagnostics  – Carla Ferrero Ruedas, CEO
• Lumina  – Guillem Loren, CEO
• Platelet Biotechnologies S.l.  – Andrea Acebes Huerta, CEO & Cofounder

Meet innovative companies developing Advanced Therapy Medicinal Products, which are innovative drugs for human used based on genes, cells or tissue engineering.

Start-ups will have the opportunity to present their business plans to a panel of investors. Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2026. 

---

Presenting companies:

• Amets Biotechnology  – Laia Trigueros Motos, CEO
• Golden Gate Biotech - Jascha Blobel, CEO
  
• Miramoon Pharma   –  Amalia Capilla,  CEO
  
• Nocturna Therapeutics   –   Miriam Corredor, CEO
• Peaches S.l.   –   Francesca Sarno, CSO
• Popcorn Therapeutics –  Iker Ausejo Mauleon,COO
• Tetraneuron SL   –   Ángel Lucio Pereira, CEO

Spain is doubling down on early-stage innovation with the launch of the Innvierte Deep-Tech & Tech Transfer programme, led by CDTI Innovación under the Ministry of Science, Innovation and Universities (MICIU), in collaboration with the European Investment Fund. With a total allocation of €353 million targeting early-stage technologies (TRL 2–4), this initiative aims to close Spain’s critical funding gap between research and commercialization—unlocking the potential of universities, research centers, and spin-offs.
This round table will explore how public-private co-investment models—such as the recent €30 million commitment into the Montana Children’s Health fund managed by Ship2B Ventures—can catalyze a stronger deep-tech ecosystem. Panelists will discuss the role of institutional capital in de-risking early innovation, the challenges of tech transfer in Spain, and how to scale breakthrough science into globally competitive companies.
Key questions include: How can Spain better align financial instruments with the needs of deep-tech entrepreneurs? What lessons can be drawn from this first Innvierte transaction? And how can investors, corporates, and public actors collaborate to accelerate the journey from lab to market?
The session is designed for investors, fund managers, tech transfer offices, policymakers, and entrepreneurs seeking to understand and engage with Spain’s evolving deep-tech financing landscape.

A guided tour of Spain’s biomedical frontier: where tomorrow’s therapies are being born, who’s driving them, which technologies enable them, and how to convert those breakthroughs into investment and company-building opportunities

Each company will be given a six-minute spotlight to unveil investment opportunities in drug development and delivery—six minutes to ignite interest and sketch the future of medicine.

Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.

---

• Vaxdyn – Juan José Infante Viñolo, CEO
  
• FatrixGel  – Pablo Sánchez-Rey Chiapasco, CEO & Founder
• Flavii Therapeutics  – Ariadna Boloix Amenós & Ainia Bellver , CEO & CSO & Co-founders
• Gate2brain – Mertixell Teixidó Turà, CEO & CSO
• i+Med S.coop –  Andrea Zapater Matute, R&D Business Developer
• Molefy Pharma - Tania Ortuño, Head of Operations
• Nanogrow Biotech – Nicolás Galmarini Galmarini, CEO & Co-founder
• Nostrum Biodiscovery –Marie-Eve Beaulieu, General Manager
• Olavide Neuron STX S.L. (ONESTX) – Ángel Cebolla Ramírez, CEO
• Ploid AI Biotech - Adolfo Gastalver, Co-Founder & CEO
• Resistia – Ignacio Massone, CEO & Co-founder